

1) Family number: 11946435 (US6004267 A)

© PatBase

Title: METHOD FOR DIAGNOSING AND STAGING PROSTATE CANCER

Abstract: The subject invention provides a method for diagnosing prostate cancer and determining preoperatively the pathological stage in patients with prostate cancer. The methods described herein can be used for prediction of margin positivity, seminal vesicle (S.V.) involvement, and lymph nodal (L.N.) involvement in patients with clinically localized prostate cancer. The method includes use of a neural network which provides prostate cancer stage information for a patient based upon input data which includes the patient's preoperative serum PSA, biopsy Gleason score, and systemic biopsy-based information. Its positive predictive value (PPV), negative predictive value (NPV), and accuracy are superior to that of current nomograms in use. Use of this method can result in enormous cost savings by accurately diagnosing patients with prostate cancer and by avoiding multiple imaging tests and expensive surgery in unindicated patients.

Classifications:


International (IPC 8-9): A61B5/06 G06F19/00

International (IPC 1-7): A01B5/00 G06F19/00

CPC: A61B5/06 A61B5/415 A61B5/418 A61B5/4381 A61B5/7267

G16H50/20 Y10S128/925

US: 128/925 600/300



Family:

Publication number	Publication date	Application number	Application date
AU199866885 A1	19980922	AU19980066885	19980306
US6004267 A	19991221	US19980036307	19980306
WO9839721 A1	19980911	WO1998US04374	19980306

Priority:

US19970039917P 19970307 WO1998US04374 19980306 US19980036307 19980306

Probable Assignee: FLORIDA UNIV OF

Assignee(s): (std): UNIV FLORIDA

Assignee(s): FLORIDA UNIV ; FLORIDA UNIV OF ; OF FLORIDA UNIV ; UNIVERSITY OF FLORIDA

Inventor(s): (std): NARAYAN PERINCHERY ; TEWARI ASHUTOSH

Inventor(s): ASHUTOSH TEWARI ; PERINCHERY NARAYAN

Designated states: AL AM AT AU AZ BA BB BE BF BG BJ BR BY CA CF CG CH CI CM CN CU CZ DE DK EE ES FI FR GA GB GE GH GM GN GR GW HU ID IE IL IS IT JP KE KG KP KR KZ LC LK LR LS LT LU LV MC MD MG MK ML MN MR MW MX NE NL NO NZ PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT UA UG UZ VN YU ZW

2) Family number: 32432093 (US2005282199 AA)


© PatBase

Title: METHOD TO PREDICT PROSTATE CANCER

Abstract: A method for predicting the probability or risk of prostate cancer is provided.

Classifications:

International (IPC 8-9): A61B19/00 A61B5/20 C12Q1/68 G01N33/48 G01N33/50 G01N33/574 G06F19/00 G06G1/00
International (IPC 1-7): C12Q1/68 G01N33/48 G01N33/50 G01N33/574 G06F19/00
CPC: C12Q1/6886 C12Q2600/112 C12Q2600/118 C12Q2600/136 G01N33/57434 G06G1/001 G16H50/70
US: 435/6 435/6.14 435/6.140P 435/6P 435/7.23 435/7.230S 702/19 702/19S



Family:

Publication number	Publication date	Application number	Application date
AU2005242724 AA	20051124	AU20050242724	20050511
CA2564208 AA	20061025	CA20052564208	20050511
EP1747466 A2	20070131	EP20050750092	20050511
US2005282199 AA	20051222	US20050126945	20050511
WO05111625 A2	20051124	WO2005US16582	20050511
WO05111625 A3	20060316	WO2005US16582	20050511

Priority:

US20040569805P 20040511 WO2005US16582 20050511 US20050126945 20050511

Probable Assignee: BAYLOR COLLEGE OF MEDICINE

Assignee(s): (std): BAYLOR COLLEGE MEDICINE ; KATTAN MICHAEL ; SLAWIN KEVIN M ; SLOAN KETTERING INST CANCER

Assignee(s): BAYLOR COLLEGE OF MEDICINE ; MEMORIAL SLOAN KETTERING CANCER CENTER

Inventor(s): (std): KATTAN MICHAEL ; SLAWIN KEVIN M

Inventor(s): KEVIN M SLAWIN ; MICHAEL KATTAN

Agent(s): PHILLIPS ORMONDE FITZPATRICK; SCHWEGMAN LUNDBERG WOESSNER AND KLUTH; SIM AND MCBURNEY

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KM KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

3) Family number: 45964934 (US2012301887 AA)

© PatBase

Title: GENE EXPRESSION PROFILING FOR THE IDENTIFICATION, MONITORING, AND TREATMENT OF PROSTATE CANCER

Abstract: A method is provided in various embodiments for determining a profile data set for a subject with prostate cancer or a condition related to prostate cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Table 1 and/or Table 8 in conjunction with PSA. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.

Classifications:

International (IPC 8-9): C12Q1/68

CPC: C12Q1/6809 C12Q1/6886 C12Q2600/112 C12Q2600/136 C12Q2600/16

US: 435/6.12 435/6.14

Figure 1A

Sample Sizes of Training and Test Subjects by Age and Group									
Age	Cut off	Number of Training Subjects by Group				Number of Test Subjects by Group			
Age	No. Subj.	High	Low	High	Low	High	Low	High	Low
40-44	2.0 ng/mL	0	0	0	0	0	0	0	0
45-49	2.0 ng/mL	0	0	0	0	0	0	0	0
50-54	2.0 ng/mL	2	0	0	0	0	0	0	0
55-59	2.0 ng/mL	3	0	0	0	0	0	0	0
60-64	2.0 ng/mL	3	0	0	0	0	0	0	0
65-69	2.0 ng/mL	3	0	0	0	0	0	0	0
70-74	2.0 ng/mL	3	0	0	0	0	0	0	0
75-79	2.0 ng/mL	3	0	0	0	0	0	0	0
80-84	2.0 ng/mL	3	0	0	0	0	0	0	0
85-89	2.0 ng/mL	3	0	0	0	0	0	0	0
90-94	2.0 ng/mL	3	0	0	0	0	0	0	0
95-99	2.0 ng/mL	3	0	0	0	0	0	0	0
Total		24	0	0	0	0	0	0	0
Median Age =		65.5	65.5	65	65	65	65	65	65.5

Figure 1B

Mean PSA Value (ng/mL) by Age and Group									
Age	Cut off	Mean PSA Value (ng/mL) by Group				Mean PSA Value (ng/mL) by Group			
Age	No. Subj.	High	Low	High	Low	High	Low	High	Low
40-44	2.0 ng/mL	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
45-49	2.0 ng/mL	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
50-54	2.0 ng/mL	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
55-59	2.0 ng/mL	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
60-64	2.0 ng/mL	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
65-69	2.0 ng/mL	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
70-74	2.0 ng/mL	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
75-79	2.0 ng/mL	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
80-84	2.0 ng/mL	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
85-89	2.0 ng/mL	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
90-94	2.0 ng/mL	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
95-99	2.0 ng/mL	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Total		1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Median PSA Value =		1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0

Family:


Publication number	Publication date	Application number	Application date
AU2010203825 AA	20100715	AU20100203825	20100106
CA2748823 AA	20100715	CA20102748823	20100106
NZ593854 A	20130222	NZ20100593854	20100106
US2012301887 AA	20121129	US20100143171	20100106
WO10080702 A2	20100715	WO2010US00037	20100106
WO10080702 A3	20101007	WO2010US00037	20100106

Priority:

US20090142789P 20090106	US20090150666P 20090206	US20090163354P 20090325
US20090170017P 20090416	US20090178342P 20090514	US20090228004P 20090723
WO2010US00037 20100106	US20100143171 20100106	

Probable Assignee: SOURCE PRECISION MEDICINE INC D B A SOURCE MDX**Assignee(s):** (std): BANKAITIS DAVIS DANUTE M ; SICONOLFI LISA ; SOURCE PREC MEDICINE INC D B A ; SOURCE PREC MEDICINE INC D B A SOURCE MDX ; STORM KATHLEEN ; WASSMANN KARL ; WEISSMANN KARL**Assignee(s):** GENOMIC HEALTH INC ; SOURCE PRECISION MEDICINE INC D B A SOURCE MDX**Inventor(s):** (std): BANKAITIS DAVIS DANUTE M ; KARL WASSMANN ; KATHLEEN STORM ; LISA SICONOLFI ; SICONOLFI LISA ; STORM KATHLEEN ; WASSMANN KARL ; WEISSMANN KARL**Agent(s):** ELRIFI IVOR R ET AL; FB RICE; FB RICE PTY LTD; SMART AND BIGGAR**Designated states:** AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW**4) Family number: 76187579 (WO19195935 A1)**

© PatBase

Title: METHODS FOR MONITORING AND TREATING PROSTATE CANCER**Abstract:** The present disclosure provides methods for monitoring prostate cancer by determining or measuring exosomal miRNA levels in a biological sample to provide a biological sample exosomal miRNA profile comprising exosomal miRNA levels and determining or measuring the level of similarity of said biological sample exosomal miRNA profile to one or more control profiles. The present disclosure also provides kits for monitoring prostate cancer progression and methods for selecting a treatment for prostate cancer.**Classifications:****International (IPC 8-9):** C12N15/113 C12Q1/6809 C12Q1/6886 G16B25/10 G16B40/00 G16B5/00**CPC:** C12Q1/6886 C12Q2600/112 C12Q2600/178 G16B25/10 G16B40/00**Family:**

Publication number	Publication date	Application number	Application date
WO19195935 A1	20191017	WO2019CA50437	20190410

Priority:

US20180655443P 20180410

Probable Assignee: UNITY HEALTH TORONTO

Assignee(s): (std): UNITY HEALTH TORONTO ; UNIV HEALTH NETWORK

Assignee(s): HEALTH NETWORK UNIV

Inventor(s): (std): FLESHNER NEIL ERIC ; YOUSEF GEORGE M

Agent(s): BERESKIN AND PARR LLP SENCRL SRL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DJ DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JO JP KE KG KH KM KN KP KR KW KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

5) Family number: 44051334 (US2009298082 AA)

© PatBase

Title: BIOMARKER PANELS FOR PREDICTING PROSTATE CANCER OUTCOMES


Abstract: This document provides methods and materials related to assessing male mammals (e.g., humans) with prostate cancer. For example, methods and materials for predicting (1) which patients, at the time of PSA reoccurrence, will later develop systemic disease, (2) which patients, at the time of retropubic radical prostatectomy, will later develop systemic disease, and (3) which patients, at the time of systemic disease, will later die from prostate cancer are provided.

Classifications:

International (IPC 8-9): C12Q1/68 C12Q1/6886 G06F19/00 G16H20/10 G16H50/20 G16H50/30

CPC: C12Q1/6886 C12Q2600/118 C12Q2600/158 C12Q2600/16 G16H20/10 G16H50/20 G16H50/30 G06F19/3431

US: 1/1 435/6 435/6.12 435/6.16 435/6.160P 435/6P 506/9 702/19



Family:

Publication number	Publication date	Application number	Application date
US2009298082 AA	20091203	US20090474879	20090529
US10407731 BB	20190910	US20150857658	20150917
US2016010162 AA	20160114	US20150857658	20150917
US2018312926 A9	20181101	US20150857658	20150917

Priority:

US20080057698P 20080530

US20090474879 20090529

US20090747879 20090529

US20150857658 20150917

Probable Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Assignee(s): (std): ANDERSON S KEITH ; BALLMAN KARLA V ; BERGSTALH ERIC J ; JENKINS ROBERT B ; KLEE GEORGE G ; KOLLMAYER THOMAS M ; MAYO FOUND MEDICAL EDUCATION AND RES ; MAYO FOUNDATION ; MAYO FOUNDATION FOR MEDICAL EDUCATION AND RES ; MORLAN BRUCE W ; NAKAGAWA TOHRU

Assignee(s): CRG SERVICING LLC ; MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Inventor(s): (std): ANDERSON S KEITH ; BALLMAN KARLA V ; BERGSTALH ERIC J ; JENKINS ROBERT B ; KLEE GEORGE G ; KOLLMAYER THOMAS K ; KOLLMAYER THOMAS M ; MORLAN BRUCE W ; NAKAGAWA TOHRU

Agent(s): FISH AND RICHARDSON PC ; KNOBBE MARTENS OLSON AND BEAR LLP

6) Family number: 69999817 (US2019383818 AA)

© PatBase

Title: METHOD FOR ESTIMATING GLEASON SCORE OF PROSTATE CANCER, METHOD FOR ESTIMATING PATHOLOGICAL STAGE, AND METHOD FOR ACQUIRING SUPPLEMENTARY INFORMATION, ALL ON THE BASIS OF SPECIFIC PSA CONTENT IN SPECIMEN

Abstract: The present invention provides methods that are for acquiring various types of supplementary information used for diagnosis or treatment of prostate cancer, and that can be implemented in a less-invasive manner at a low cost. Provided are, by measuring the content of prostate specific antigen (PSA) having a beta -N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a specimen, and comparing the measured value with a threshold value, (1) a method for estimating whether a Gleason score (primary pattern and secondary pattern) is not less than or less than a prescribed value, (2) a method for estimating whether the pathological stage (pT) is not less than or less than a prescribed value, and (3) a method for acquiring information for assessment indicating diagnosis or treatment should be actively conducted because a GS at gross total removal is expected to be higher than a GS at biopsy.

Classifications:

International (IPC 8-9): C12Q1/02 G01N21/64 G01N33/543 G01N33/574

CPC: G01N2021/6417 G01N21/553 G01N21/648 G01N2333/4724


G01N2333/96455 G01N2400/40 G01N2800/56 G01N33/57434

G01N33/57484 G01N33/57488

JP F-Term: 2G043 2G045 2G043/AA01 2G043/AA03 2G043/BA16

2G043/EA01 2G043/EA14

JP F-Index: G01N21/64@G G01N33/574@B



Family:

Publication number	Publication date	Application number	Application date
EP3550304 A1	20191009	EP20170877115	20171129
EP3550304 A4	20191009	EP20170877115	20171129
JP2018101327 A1	20191024	JP20180554193T	20171129
US2019383818 AA	20191219	US20170464744	20171129
WO18101327 A1	20180607	WO2017JP42802	20171129

Priority:

JP20160231322 20161129 WO2017JP42802 20171129

Probable Assignee: HIROSAKI UNIV

Assignee(s): (std): KONICA MINOLTA INC ; UNIV HIROSAKI

Assignee(s): HIROSAKI UNIV ; KONICA MINOLTA HOLDINGS INC ; コニカミノルタ株式会社 ; 国立大学法人弘前大学

Inventor(s): (std): KANEKO TOMONORI ; KAYA TAKATOSHI ; OHYAMA CHIKARA ; TOBISAWA YUKI ; YONEYAMA TOHRU

Inventor(s): 大山 力 ; 彼谷 高敏 ; 米山 徹 ; 金子 智典 ; 飛澤 悠葵

Agent(s): HENKEL AND PARTNER MBB; SSINPAT PATENT FIRM; 特許業務法人SSINPAT

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DJ DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JO JP KE KG KH KM KN KP KR KW KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

7) Family number: 57613464 (US2014315192 AA)

© PatBase

Title: CHARACTERIZING PROSTATE CANCER

Abstract: Methods and kits for predicting the course or aggressiveness of prostate cancer include detecting the methylation status of various genes.

Classifications:

International (IPC 8-9): C12Q1/68

CPC: C12Q1/6886 C12Q2600/154

US: 435/6.11

Family:

Publication number	Publication date	Application number	Application date
US2014315192 AA	20141023	US20130787422	20130306

Priority:

US20130787422 20130306

Probable Assignee: VERIDEX LLC

Assignee(s): (std): CHOWDARY DONDPATI ; MAZUMDER ABHIJIT ; MEHROTRA JYOTI ; VARDE SHOBHA ; VENER TATIANA ; VERIDEX LLC ; WANG HAIYING

Inventor(s): (std): CHOWDARY DONDPATI ; MAZUMDER ABHIJIT ; MEHROTRA JYOTI ; VARDE SHOBHA ; VENER TATIANA ;

8) Family number: 65372658 (US2018348223 AA)

© PatBase

Title: METHOD FOR ESTIMATING PATHOLOGICAL TISSUE DIAGNOSIS RESULT (GLEASON SCORE) OF PROSTATE CANCER

Abstract: Provided is a method of obtaining an index value used for pathological tissue diagnosis of prostate cancer, which method has low invasiveness and can be performed at a low cost. The method is a method of estimating a Gleason score that represents the malignancy of prostate cancer, which method includes: measuring the content of a prostate-specific antigen having an N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a sample; and estimating that the Gleason score is 7 or higher when the thus measured value is larger than a threshold value, or estimating that the Gleason score is 6 or lower when the measured value is smaller than a threshold value. The prostate-specific antigen is preferably quantified by a method including the step of binding a molecule having an affinity for beta -N-acetylgalactosamine residue, such as *Wisteria floribunda* lectin, soybean agglutinin, *Vicia Villosa* lectin or an anti- beta -N-acetylgalactosamine antibody, to the prostate-specific antigen.

Classifications:

International (IPC 8-9): C07K14/435 C07K16/18 C12N5/09 C12Q1/02 G01N33/53 G01N33/543 G01N33/574



CPC: G01N2440/38 G01N33/53 G01N33/543 G01N33/57434

US: 1/1 436/501

JP F-Term: 2G045 4B065 4H045 4B065/AA90 4B065/AC20 4B065/CA46 4H045/AA10 4H045/AA30 4H045/CA40 4H045/DA76 4H045/DA80 4H045/EA50 4H045/FA74

JP F-Index: C07K14/435 C07K16/18 C12N05/09 G01N33/53@V G01N33/543,595 G01N33/574@B

PatBase - US2018348223_AA

FIG. 1A**FIG. 1B****Family:**

Publication number	Publication date	Application number	Application date
DE602016024871 D1	20191212	DE201660024871T	20160902
EP3358352 A1	20180808	EP20160851020	20160902
EP3358352 A4	20180808	EP20160851020	20160902
EP3358352 B1	20191120	EP20160851020	20160902
JP2017056844 A1	20180712	JP20170543048T	20160902
JP6729595 B1	20200722	JP20170543048T	20160902
US2018348223 AA	20181206	US20160761637	20160902
WO17056844 A1	20170406	WO2016JP75771	20160902

Priority:

JP20150189611 20150928 EP20160851020 20160902 WO2016JP75771 20160902

Probable Assignee: KONICA MINOLTA HOLDINGS INC

Assignee(s): (std): KONICA MINOLTA HOLDINGS INC ; KONICA MINOLTA INC

Assignee(s): KONICA MINOLTA CO LTD ; コニカミノーラ株式会社

Inventor(s): (std): KANEKO TOMONORI ; KAYA TAKATOSHI

Inventor(s): 彼谷 高敏 ; 金子 智典

Agent(s): CURRAN CLAIR; HENKEL AND PARTNER MBB PATENTANWALTSKANZLEI RECHTSANWALTSKANZLEI; SSINPAT PATENT FIRM; 特許業務法人SSINPAT

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

9) Family number: 60056750 (US2017168059 AA)

© PatBase

Title: BIOMARKERS FOR ASSESSING CANCER PATIENTS FOR TREATMENT

Abstract: A method for selecting treatment options for patients is provided. The method comprises a procedure for selecting patients that should not be placed on Active Surveillance (AS) but receive active treatment even though the morphologic analysis of the patient's biopsy may show a Gleason score that would traditionally have placed the patient in AS without any further treatment. In accordance with one embodiment, the patient is selected for active treatment if a biomarker associated with prostate cancer is detected. In yet a further embodiment, the patient is selected for additional treatment if the biomarker's concentration is determined to be higher in the benign section of the tissue sample than in the cancerous section. In another embodiment, biochemical recurrence is predicted identifying patients for treatment.

Classifications:

Layer	Dilution	Antibody	Origin	Cat. #	Lot #	Company
1	100	Ki67	Rabbit	9027S	1-2	Cell Signalling
2	100	EZH2	Mouse	612667	3144566	BD Transduction Laboratories
3	200	CACNAID	Mouse	TA309307	0908	Origene
4	40	Her2/neu	Mouse	OP15	d00131255	Calbiochem (EMD)
5	1000	-7 ProPSA	Mouse	PS2P309.2	M0404-66-102	Beckman Coulter
6	250	Periostin	Rabbit	ab14041	GR134839-1(n/a)	abcam

FIG. 1

Family:

Publication number	Publication date	Application number	Application date
US2017168059 AA	20170615	US20150116925	20150209
WO15120416 A1	20150813	WO2015US15074	20150209

Priority:

US20140937075P 20140207 WO2015US15074 20150209 US20150116925 20150209

Probable Assignee: UNIV JOHNS HOPKINS

Assignee(s): (std): UNIV JOHNS HOPKINS

Assignee(s): JOHNS HOPKINS UNIV ; SEC DEP OF HEALTH AND HUMAN SERVICES AS US GOV

Inventor(s): (std): CARTER H BALLANTINE ; CHRISTUDASS CHRISTHUNESA ; CHUNG JOON YONG ; DAVIS CHRISTINE ; EPSTEIN JONATHAN I ; HEWITT STEPHEN M ; LIU ZHI ; VELTRI ROBERT W ; ZHANG HUI ; ZHU GUANGJING

Agent(s): MORALES JOSEPH ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU

CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN
IR IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX
MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN
ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

10) Family number: 74861600 (WO19122037 A1)

© PatBase


Title: PRE-SURGICAL RISK STRATIFICATION BASED ON PDE4D7 EXPRESSION AND PRE-SURGICAL CLINICAL VARIABLES

Abstract: The invention relates to a method of pre-surgical risk stratification of a prostate cancer subject, comprising determining a gene expression profile for phosphodiesterase 4D variant 7 (PDE4D7) in a biological sample obtained from the subject, determining an expression based risk score for the subject based on the gene expression profile, and determining a pre-surgical prognostic risk score for the subject based on the expression based risk score and pre-surgical clinical variables of the subject. This may allow for an improved stratification of the subject in a pre-surgical setting that may result in better primary treatment decisions. For instance, the pre-surgical prognostic risk score may allow to make better recommendations on whether to select active surveillance vs. active intervention, e.g., radical prostatectomy, for certain sub-populations of prostate cancer patients.

Classifications:

International (IPC 8-9): C12Q1/6886

CPC: C12Q1/6886 C12Q2600/112 C12Q2600/118 C12Q2600/158



Family:

Publication number	Publication date	Application number	Application date
EP3502280 A1	20190626	EP20170209506	20171221
WO19122037 A1	20190627	WO2018EP86015	20181219

Priority:

EP20170209506 20171221

Probable Assignee: PHILIPS KONINKLL NV

Assignee(s): (std): PHILIPS KONINKLL NV

Inventor(s): (std): HOFFMANN RALF

Inventor(s): HOFFMANN RALF DIETER

Agent(s): COOPS PETER ET AL; DE HAAN POUL ERIK

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DJ DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JO JP KE KG KH KM KN KP KR KW KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

11) Family number: 55763258 (US2014045193 AA)

© PatBase


Title: METHIONINE METABOLITES PREDICT AGGRESSIVE CANCER PROGRESSION

Abstract: The invention relates to the use of enzymes and nanorods to detect cysteine level in a patient sample and relates to the use of the detected cysteine level to predict cancer recurrence in the patient. The invention is directed to systems and methods of detecting cysteine level in a sample from a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. This invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject and treating the subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage.

Classifications:

International (IPC 8-9): C12M1/40 C12N9/88 C12Q1/00 C12Q1/06

C12Q1/527 G01N1/31 G01N21/25 G01N27/327 G01N27/416 G01N33/68
CPC: C12Q1/527 G01N2800/54 G01N33/57484 G01N33/587
G01N33/6815 G01N33/6893 C12N9/88 C12Q1/005 C12Y402/01022
C12Y404/01001 G01N2333/90 G01N2333/988
US: 204/403.14 205/777.5 435/232 435/283.1 435/4 435/7.8



Family:

Publication number	Publication date	Application number	Application date
AU2013299409 AA	20140213	AU20130299409	20130809
CA2880928 AA	20150202	CA20132880928	20130809
EP2882862 A2	20150617	EP20130828540	20130809
EP2882862 A4	20160720	EP20130828540	20130809
IN01130DN2015 A	20160831	IN2015DN01130	20150212
MX2015001788 A1	20150928	MX20150001788	20130809
US2014045193 AA	20140213	US20130963922	20130809
US2015204882 AA	20150723	US20150617016	20150209
WO14026157 A2	20140213	WO2013US54415	20130809
WO14026157 A3	20140508	WO2013US54415	20130809

Priority:

US20120682155P 20120810 WO2013US54415 20130809 US20130963922 20130809
US20140021648P 20140707 US20150617016 20150209

Probable Assignee: CEDARS SINAI MEDICAL CENTER

Assignee(s): (std): CEDARS SINAI MEDICAL CENTER

Assignee(s): BHOWMICK NEIL A ; CHOUDHURY DIPTIMAN

Inventor(s): (std): BHOWMICK NEIL A ; CHOUDHURY DIPTIMAN

Inventor(s): DIPTIMAN CHOUDHURY ; NEIL A BHOWMICK

Agent(s): BCF LLP; CARE ALISON; FB RICE; FB RICE PTY LTD; LEVY SETH D ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

12) Family number: 53782023 (US2016018400 AA)

© PatBase

Title: DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR PROSTATE CANCER AND OTHER DISORDERS

Abstract: The present invention relates to the use of VPS28 and/or VPS13A as biomarkers for diagnosing prostate cancer, prostate intraepithelial neoplasia (PIN) or atypical small acinar proliferation (ASAP) and to the use of VPS13A, VPS28 and/or NAALADL2 as biomarkers for predicting the prognosis of prostate cancer. The invention also relates to the use of VPS13A, VPS28 and/or NAALADL2 as biomarkers for determining the grade or pathological stage of prostate cancer and monitoring progression of prostate cancer. In addition, the invention relates to the use of NAALADL2 as a biomarker for diagnosing colon, pancreatic or breast cancer. Assays, systems and storage media based on the use of these biomarkers are also provided.

Classifications:

International (IPC 8-9): C12N15/00 C12N15/09 C12Q1/68 G01N33/574 G01N33/68


CPC: C12Q1/6886 C12Q2600/112 C12Q2600/118 C12Q2600/158

G01N2333/4703 G01N2333/948 G01N33/57434

US: 435/23 435/6.11 435/6.12 435/7.23 435/7.92 436/501 436/86 506/2 506/9

JP F-Term: 2G045/4B024 4B063/4H045 2G045/AA13 2G045/AA16 2G045/AA22 2G045/AA24 2G045/AA26 2G045/BA13 2G045/BB20 2G045/BB24 2G045/CA25 2G045/CA26 2G045/CB01 2G045/CB02 2G045/CB03 2G045/CB04 2G045/CB14 2G045/CB26 2G045/DA14 2G045/DA36 2G045/FA29 2G045/FB01 2G045/FB03 2G045/FB15 2G045/GC10 2G045/GC12 2G045/JA01 2G045/JA03 4B024/AA12 4B024/CA01 4B024/CA09 4B024/CA11 4B024/GA30 4B024/HA12 4B063/QA01 4B063/QA19 4B063/QQ03 4B063/QQ42 4B063/QQ53 4B063/QR32 4B063/QR55 4B063/QR62 4B063/QS25 4B063/QS34 4B063/QX02 4H045/AA30 4H045/BA10 4H045/CA40 4H045/EA51

JP F-Index: C07K14/47 C12N15/00@A C12N15/00,ZNA C12Q1/68@A



Family:

Publication number	Publication date	Application number	Application date
AU2014229765 AA	20151008	AU20140229765	20140313
CA2905314 AA	20150910	CA20142905314	20140313
CN105209641 A	20151230	CN201480028108	20140313
EP2971081 A1	20160120	EP20140713567	20140313
GB201304612 A0	20130501	GB20130004612	20130314
IN09144DN2015 A	20160422	IN2015DN09144	20151005
JP2016510986 T2	20160414	JP20150562317T	20140313
US2016018400 AA	20160121	US20140773580	20140313
WO14140594 A1	20140918	WO2014GB50767	20140313

Priority:

GB20130004612 20130314 WO2014GB50767 20140313

Probable Assignee: CANCER REC TECH LTD

Assignee(s): (std): CANCER REC TECH LTD

Assignee(s): CANCER RESEARCH TECHNOLOGY LIMITED ; CANCER RESEARCH TECHNOLOGY LTD ; NEAL DAVID ; WHITAKER HAYLEY ; キンサー リサーチ テクノロジー リミテッド ; キンサー・リサーチ・テクノロジー・リミテッド ; 癌症研究技术有限公司

Inventor(s): (std): NEAL DAVID ; WHITAKER HAYLEY

Inventor(s): ウィテカー ハイレイ ; ウィテカー、ハイレイ ; ニール デヴィッド ; ニール、デヴィッド ; 大卫 尼尔 ; 海利 惠特克

Agent(s): ARAI EIICHI; FB RICE; FB RICE PTY LTD; FUJITA TAKASHI; HAYES EMILY ANNE LUXFORD; HAYES EMILY ET AL; HIRAKI YUSUKE; NORTON ROSE FULBRIGHT CANADA LLP SENCRL SRL; TANAKA NATSUO; 北京康信知识产权代理有限公司 11240; 平木 祐輔; 新井 栄一; 李海霞; 村林 望; 沈敬亭; 田中 夏夫; 菊田 尚子; 藤田 節

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

13) Family number: 29962140 (US5993388 A)

© PatBase

Title: Nomograms to aid in the treatment of prostatic cancer

Abstract: This invention relates to methods and apparatus for predicting probability of cancer recurrence following radical prostatectomy using predetermined clinical and pathological factors. The invention includes nomograms which can be used preoperatively and postoperatively in patients diagnosed with prostatic adenocarcinoma to aid in selection of an appropriate course of therapy.


Classifications:

International (IPC 8-9): C12Q1/68 G06F19/00 G06G1/00

International (IPC 1-7): A61B1/900 A61B19/00 A61B5/00

CPC: G06G1/001 C12Q1/6886 C12Q2600/106

US: 128/898 600/300

**Family:**

Publication number	Publication date	Application number	Application date
US5993388 A	19991130	US19980104218	19980625
US6409664 BA	20020625	US19990444706	19991124

Priority:

US19970051428P 19970701 US19970051478P 19970701 US19980104218 19980625
 US19990444706 19991124

Probable Assignee:

KATTAN MICHAEL W

Assignee(s): (std):

KATTAN MICHAEL W ; SCARDINO PETER T

Inventor(s): (std):

KATTAN MICHAEL W ; SCARDINO PETER T

Inventor(s):

MICHAEL W KATTAN ; PETER T SCARDINO

Agent(s):

HELLER EHRMAN WHITE MCAULIFFE


14) Family number: 65616292 (WO17077162 A1)

© PatBase

Title: IN VITRO METHOD FOR DIAGNOSING PROSTATE CANCER

Abstract: The invention relates to a method for the sensitive and specific in vitro differential diagnosis of prostate cancer, which comprises partially purifying prostate-specific antigen in a fluid sample isolated from a subject to subsequently determine the percentage of sialic acid a-2,3 of the prostate-specific antigen and/or the proportion (ratio) of internal fucosylation of the prostate-specific antigen. The invention relates particularly to a highly sensitive and specific method that allows samples from high-risk prostate cancer patients to be distinguished from samples from patients with benign disorders or diseases of the prostate and low- or intermediate-risk prostate cancer patients. The method can also be used for the prognosis of this cancer. The invention also relates to kits for carrying out said diagnosis methods.

Classifications:**International (IPC 8-9):** G01N33/574**CPC:** G01N33/574



Family:

Publication number	Publication date	Application number	Application date
ES2615538 AA	20170607	ES20150031608	20151106
ES2615538 BA	20180322	ES20150031608	20151106
W017077162 A1	20170511	W02016ES70781	20161104

Priority:

ES20150031608 20151106

Probable Assignee: FUND INST D INVESTIGACIO BIOMEDICA DE GIRONA DR JOSEP TRUETA

Assignee(s): (std): FUND INST D INVESTIGACIO BIOMEDICA DE GIRONA DR JOSEP TRUETA ; FUNDACIO INST D INVESTIGACIO BIOMEDICA DE GIRONA DR JOSEP TRUETA ; UNIV GIRONA

Assignee(s): UNIVERSITAT DE GIRONA

Inventor(s): (std): ALEIXANDRE CERAROLS ROSA NURIA ; BARRABES VERA SILVIA ; COMET BATLLE JOSEP ; DE LLORENS DURAN RAFAEL ; FAHEY RADKA ; FERRER BATALLE MONTSEERAT ; LLOP ESCORIHUELA ESTHER ; PERACAU LA MIRO ROSA ; RAMIREZ MALAGON MANEL ; RUDD PAULINE MARY

Inventor(s): ESTHER LLOP ESCORIHUELA ; JOSEP COMET BATLLE ; MANEL RAMIREZ MALAGON ; MONTSEERAT FERRER BATALLE ; PAULINE MARY RUDD ; RADKA FAHEY ; RAFAEL DE LLORENS DURAN ; ROSA NURIA ALEIXANDRE CERAROLS ; ROSA PERACAU LA MIRO ; SILVIA BARRABES VERA

Agent(s): ZEA BERNABE; ZEA CHECA BERNA

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DJ DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KW KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

15) Family number: 51155572 (US2015051084 AA)

© PatBase

Title: METHOD FOR DETERMINING PROGNOSIS OF PROSTATE CANCER IN A SUBJECT


Abstract: A method for determining the prognosis of prostate cancer in a subject is provided which comprises the assessment of the methylation status of the HSPB1 gene in a prostate cancer sample.

Classifications:

International (IPC 8-9): C07H21/04 C12Q C12Q1/68

CPC: C12Q1/6886 C12Q2600/118 C12Q2600/154 C12Q2600/158 C12Q2600/16

US: 506/2 536/24.31 1/1



Family:

Publication number	Publication date	Application number	Application date
DE602013031911 D1	20180222	DE201360031911T	20130319
EP2828404 A1	20150128	EP20130721011	20130319
EP2828404 B1	20180110	EP20130721011	20130319
GB201204785 A0	20120502	GB20120004785	20120319
HK1200502 A1	20150807	HK20150101066	20150130
HK1200502 B	20180907	HK20150101066	20150130
US2015051084 AA	20150219	US20130386292	20130319
US9845506 BB	20171219	US20130386292	20130319
WO13140161 A1	20130926	WO2013GB50714	20130319

Priority:

GB20120004785 20120319 EP20130721011 20130319 WO2013GB50714 20130319

Probable Assignee: QUEEN MARY UNIV OF LONDON

Assignee(s): (std): QUEEN MARY AND WESTFIELD COLLEGE ; QUEEN MARY UNIV OF LONDON ; UNIV LONDON QUEEN MARY

Assignee(s): QUEEN MARY AND WESTFIELD COLLEGE UNIV OF LONDON

Inventor(s): (std): AHMAD AMAR ; LORINCZ ATTILA ; VASILJEVIC NATASA

Inventor(s): AMAR AHMAD ; ATTILA LORINCZ ; NATASA VASILJEVIC

Agent(s): BASSIL NICHOLAS; BASSIL NICHOLAS CHARLES; LETTERS AND THOO LTD; STRADLEY RONON STEVENS AND YOUNG LLP

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

16) Family number: 64915788 (US2018230547 AA)

© PatBase

Title: METHODS FOR PREDICTING PROSTATE CANCER RELAPSE


Abstract: The present invention relates to methods for determining whether a subject having prostate cancer is at an increased risk for relapse or rapid relapse. It is based, at least in part, on the results of a comprehensive genome analysis of 273 prostate cancer samples, which indicate that the percentage of large size CNVs predicts prostate cancer relapse. In certain embodiments, a method for determining whether a prostate cancer patient has an increased risk of suffering a relapse or a rapid relapse comprises determining the number and size of CNVs in a sample and determining a large size ratio, where if the large size ratio exceeds a particular threshold, the patient is deemed to be at an increased risk for relapse or rapid relapse.

Classifications:

International (IPC 8-9): C12Q1/68 C12Q1/6886

CPC: C12Q1/6837 C12Q1/6886 C12Q2600/118 C12Q2600/156

US: 1/1 424/277.1



Family:

Publication number	Publication date	Application number	Application date
CA2994848 AA	20180205	CA20162994848	20160808
EP3332037 A1	20180613	EP20160835759	20160808
EP3332037 A4	20190313	EP20160835759	20160808
US2018230547 AA	20180816	US20180890789	20180207
WO17027473 A1	20170216	WO2016US46051	20160808
WO17027473 A8	20171130	WO2016US46051	20160808

Priority:

US20150202532P 20150807 WO2016US46051 20160808 US20180890789 20180207

Probable Assignee: UNIV OF PITTSBURGH OF COMMW SYSTEM OF HIGHER EDUCATION

Assignee(s): (std): UNIV OF PITTSBURGH OF COMMW SYSTEM OF HIGHER EDUCATION ; UNIV PITTSBURGH COMMW SYS HIGHER EDUCATION

Assignee(s): LIU SHUCHANG ; LUO JIANHUA ; MICHALOPOULOS GEORGE ; NELSON JOEL ; OF PITTSBURGH OF COMMW SYSTEM OF HIGHER EDUCATION UNIV ; TSENG CHIEN CHENG ; YU YANPING

Inventor(s): (std): LIU SHUCHANG ; LOU JIANHUA ; LUO JIANHUA ; MICHALOPOULOS GEORGE ; NELSON JOEL ; TSENG CHIEN CHENG ; YU YANPING

Agent(s): BARKER BRETTELL LLP; BERESKIN AND PARR LLP SENCRL SRL; KOLE LISA B

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

17) Family number: 34329266 (US2007065856 AA)

© PatBase

Title: MOLECULAR METHOD FOR DIAGNOSIS OF PROSTATE CANCER

Abstract: Methods for diagnosing or detecting cancerous prostate tissue. A panel of 8 specific marker genes are provided. The overexpression of some of these marker genes compared to their expression in normal prostate tissue and the underexpression of the rest of these marker genes are indicative of cancerous prostate tissue. By using these 8 marker genes as a diagnostic tool, smaller tissue samples, such as those obtained by core needle biopsies can be used.

Classifications:

International (IPC 8-9): C12N15/10 C12N15/12 C12N15/16 C12N15/18 C12N15/54 C12N15/57 C12Q1/04 C12Q1/68 C40B30/04 G01N33/53 G01N33/574

CPC: C12Q1/6886 C12Q2600/112 C12Q2600/158 G01N33/57434

US: 435/6 435/6.14 435/6.140P 435/6P 435/7.23 435/7.230S




Figure 1

Family:

Publication number	Publication date	Application number	Application date
AT486964 E	20101115	AT20060790654T	20060908
CA2622440 AA	20080313	CA20062622440	20060908
DE602006018038 D1	20101216	DE200660018038T	20060908
EP1934367 A1	20080625	EP20060790654	20060908
EP1934367 A4	20081015	EP20060790654	20060908
EP1934367 B1	20101103	EP20060790654	20060908
ES2355430 T3	20110325	ES20060790654T	20060908
US2007065856 AA	20070322	US20060519892	20060913
US7759060 BB	20100720	US20060519892	20060913
WO07030919 A1	20070322	WO2006CA01477	20060908

Priority:

US20050716507P 20050914 WO2006CA01477 20060908 US20060519892 20060913

Probable Assignee: NATIONAL RESEARCH COUNCIL OF CANADA

Assignee(s): (std): BELACEL NABIL ; CA NAT RESEARCH COUNCIL ; CANADA NAT RES COUNCIL ; CUPERLOVIC CULF MIROSLAVA ; NAT RES COUNCIL CANADA OTTAWA ; NAT RES COUNCIL OF CANADA OTTA ; OUELLETTE RODNEY

Assignee(s): NATIONAL RESEARCH COUNCIL OF CANADA ; NATIONAL RESEARCH COUNCIL OF CANADA OTTAWA

Inventor(s): (std): BELACEL NABIL ; CUPERLOVIC CULF MIROSLAVA ; OUELLETTE RODNEY

Agent(s): BRION; BRION ARTURO; CASSAN MACLEAN; PARRY CHRISTOPHER STEPHEN

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

18) Family number: 33103246 (US2008254470 AA)

© PatBase

Title: METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE PROGNOSIS OF CELL PROLIFERATIVE DISORDERS

Abstract: The present application provides methods and nucleic acids for providing a prognosis of cell proliferative disorders, most preferably cancer but not breast cancer.

Classifications:

International (IPC 8-9): C07H21/00 C07H21/04 C12N15/09 C12Q1/00

C12Q1/68 C40B30/04 G01N1/30 G01N33/53 G01N33/574

CPC: C12Q1/6886 C12Q2600/106 C12Q2600/118 C12Q2600/154

C12Q2600/158 C12Q2600/16 G01N2800/60 G01N33/57434

US: 1/1 435/40.52 435/40.520S 435/6 435/6.11 435/6.14 435/6.140P

435/6.16 435/6.160P 435/6P 435/7.23 435/7.230S 506/9 506/9S

536/23.1 536/23.100S 536/23.5 536/23.500S

JP F-Term: 2G045 4B024 4B063 4B024/AA12 4B024/CA03 4B024/CA04

4B024/CA09 4B024/CA11 4B024/CA12 4B024/HA14 4B063/QA12

4B063/QA19 4B063/QQ42 4B063/QQ52 4B063/QQ53 4B063/QR55


4B063/QR62 4B063/QR82 4B063/QS25 4B063/QS34 4B063/QA01

4B063/QA18 4B063/QQ02 4B063/QQ08 4B063/QR08 4B063/QR32

4B063/QR42 4B063/QR50 4B063/QR72 4B063/QR77 4B063/QS16

4B063/QS28 4B063/QS36 4B063/QS39 4B063/QX02

JP F-Index: C12N15/00@A C12Q1/68@A C12Q1/6886@C
C12Q1/6886@Z G01N33/53@M G01N33/574@A C12N15/00,ZNA@A
C12Q1/68,ZNA@A
JP Facet: ZNA



Family:

Publication number	Publication date	Application number	Application date
AT438740 E	20090815	AT20050853011T	20051202
AU2005322435 AA	20060706	AU20050322435	20051202
AU2005322435 BB	20120223	AU20050322435	20051202
CA2593546 AA	20060706	CA20052593546	20051202
DE602005015893 D1	20090917	DE200560015893T	20051202
DE602005045826 D1	20150326	DE200560045826T	20051202
DE602006041603 D1	20140618	DE200660041603T	20061004
DK1943356 T3	20140818	DK20060806038T	20061004
EP1831399 A2	20070912	EP20050853011	20051202
EP1831399 B1	20090805	EP20050853011	20051202
EP1943356 A2	20080716	EP20060806038	20061004
EP1943356 B1	20140514	EP20060806038	20061004
EP2213749 A1	20100804	EP20090010002	20051202
EP2280084 A1	20110202	EP20100177053	20051202
EP2280084 B1	20150211	EP20100177053	20051202
EP2284279 A1	20110216	EP20100177065	20051202
EP2311984 A1	20110420	EP20100177084	20051202
EP2311984 A8	20111228	EP20100177084	20051202
ES2331146 T3	20091222	ES20050853011T	20051202
ES2491895 T3	20140908	ES20060806038T	20061004
ES2534139 T3	20150417	ES20100177053T	20051202
JP2008522590 T2	20080703	JP20070544601T	20051202
JP5745202 B2	20150708	JP20070544601T	20051202
JP2012120538 A2	20120628	JP20120036858	20120222
JP5883677 B2	20160315	JP20120036858	20120222
SI1943356 T1	20140930	SI20060031811T	20061004
US2009197250 AA	20090806	US20050720744	20051202
US2008254470 AA	20081016	US20060089021	20061004
US2016312287 AA	20161027	US20150757840	20151223
WO06071466 A2	20060706	WO2005US43974	20051202
WO06071466 A3	20070315	WO2005US43974	20051202
WO06071466 A8	20090618	WO2005US43974	20051202
WO07039290 A2	20070412	WO2006EP09605	20061004
WO07039290 A3	20070913	WO2006EP09605	20061004
WO07039291 A2	20070412	WO2006EP09606	20061004
WO07039291 A3	20080110	WO2006EP09606	20061004

Priority:

US20040632426P 20041202	US20040633250P 20041202	US20050662220P 20050314
US20050723125P 20051003	US20050723054P 20051003	US20050740736P 20051130
US20050740923P 20051130	WO2005US43974 20051202	EP20100177053 20051202
EP20050853011 20051202	EP20090010002 20051202	JP20070544601 20051202
JP20070544601T 20051202	US20050720744 20051202	EP20060090106 20060615
EP20060806038 20061004	WO2006EP09605 20061004	US20060089021 20061004
US20070720744 20071102	US20150757840 20151223	

Probable Assignee: EPIGENOMICS AG

Assignee(s): (std): BERLIN KURT ; COTTRELL SUSAN ; DISTLER JUERGEN ; EPIGENOMICS AG ; HAEFLIGER CAROLINA ; MODEL FABIAN ; PIPENBROCK CHRISTIAN ; SKILLMAN THOMAS L ; SLEDZIEWSKI ANDREW Z ; SONG XIAOLING ; THOMAS JEFFREY G ; WEISS GUNTER

Assignee(s): エピゲノミクス アクチエンゲゼルシャフト

Inventor(s): (std): BERLIN KURT ; COTTRELL SUSAN ; DISTLER JUERGEN ; DISTLER JURGEN ; HAEFLIGER CAROLINA ; MODEL FABIAN ; PIPENBROCK CHRISTIAN ; SKILLMAN THOMAS ; SKILLMAN THOMAS L ; SLEDZIEWSKI ANDREW ; SLEDZIEWSKI ANDREW Z ; SONG XIAOLING ; THOMAS JEFFREY G ; WEISS GUNTER

Inventor(s): ANDREW Z SLEDZIEWSKI ; CAROLINA HAEFLIGER ; COTTRELL SUSAN SEATTLE ; FABIAN MODEL ; GUNTER WEISS ; JEFFREY G THOMAS ; JURGEN DISTLER ; SKILLMAN THOMAS L KENNYDALE ; SLEDZIEWSKI ANDREW Z SHORELINE ; SONG XIAOLING WOODINVILLE ; SUSAN COTTRELL ; THOMAS JEFFREY G SAN FRANCISCO ; THOMAS L SKILLMAN ; XIAOLING SONG ; コートレル スーザン ; スキルマン トーマス エル ; スレジウスキー アンド リュー ゼット ; ソン シャオリン ; ディシュトラ ユールゲン ; トーマス エフラー ジー ; ヘアラー カロリナ ; モデル ファビアン ; ヴァイス ガンター

Agent(s): ASAI KENJI ; CURELL MIREIA ; DAVIES COLLISON CAVE ; DAVIES COLLISON CAVE PTY LTD ; DAVIS WRIGHT TREMAINE LLP SEATTLE ; HAKODA ATSUSHI ; KRAUSS JAN ; KUMAKURA YOSHIO ; LAZCANO JESUS ; ZSP

PATENTANWALTE PARTG MBB; ZWICKER JOERK; 浅井 賢治; 熊倉 禎男; 箱田 篤

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

19) Family number: 29022160 (US2004038240 AA)

© PatBase

Title: METHOD AND MATERIALS FOR ASSESSING CANCER AGGRESSIVENESS

Abstract: The invention involves the predicting the aggressiveness of cancer. Specifically, the invention provides methods and materials for evaluating the ratio of CB to stefin A such that the aggressiveness of cancer can be predicted.

Classifications:

International (IPC 8-9): C12Q1/68 C12Q1/6886 G01N33/574

International (IPC 1-7): C12N9/64 C12P19/34 C12Q1/37 C12Q1/68 G01N33/53 G01N33/574

CPC: C12Q1/6886 C12Q2600/158 C12Q2600/112 G01N2333/8139 G01N33/574 G01N33/57434

US: 435/6 435/6.14 435/6.140P 435/6P 435/91.2 435/91.200S




FIG. 1A

Family:

Publication number	Publication date	Application number	Application date
AU200222945 A1	20020130	AU20020022945	20010713
AU200222945 A5	20020130	AU20020022945	20010713
AU200222945 AA	20020130	AU20020022945	20010713
US2004038240 AA	20040226	US20030332628	20030612
WO0206530 A2	20020124	WO2001US22072	20010713
WO0206530 A3	20030828	WO2001US22072	20010713

Priority:

US20000217974P 20000713 WO2001US22072 20010713 US20030332628 20030612

Probable Assignee: OF MINNESOTA UNIV

Assignee(s): (std): QUAST BARRY J ; SINHA AKHOURI ; UNIV MINNESOTA ; WILSON MICHAEL J

Assignee(s): OF MINNESOTA UNIV ; REGENTS OF THE UNIVERSITY OF MINNESOTA ; UNIV

Inventor(s): (std): QUAST BARRY J ; SINHA AKHOURI ; WILSON MICHAEL J

Inventor(s): AKHOURI SINHA ; BARRY J QUAST ; MICHAEL J WILSON

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EE ES FI FR GA GB GD GE GH GM GN GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NE NL NO NZ PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

20) Family number: 74866710 (WO20157070 A1)

© PatBase


Title: NOVEL BIOMARKERS AND DIAGNOSTIC PROFILES FOR PROSTATE CANCER

Abstract: The present invention relates to biomarkers and diagnostic profiles based on the expression status of particular genes for use in the diagnosis of prostate cancer, in particular the early detection of prostate cancer and prediction of disease progression and Gleason greater than or equal to 4 cancer. The present invention also provides methods of diagnosis and treatment of prostate cancer, and kits for the early detection of prostate cancer based on the expression status of the biomarkers in biological samples, in particular urine samples.

Classifications:

International (IPC 8-9): C12Q1/6886 G16B25/10 G16H50/20 G16H50/70

CPC: C12Q1/6886 C12Q2600/158 G16B25/10 G16H50/20 G16H50/70

**Family:**

Publication number	Publication date	Application number	Application date
GB201905111 A0	20190522	GB20190005111	20190410
WO20157070 A1	20200806	WO2020EP52054	20200128

Priority:

US20190797437P 20190128 GB20190005111 20190410

Probable Assignee: UEA ENTERPRISES LTD

Assignee(s): (std): UEA ENTERPRISES LTD

Inventor(s): (std): BREWER DANIEL SIMON ; CLARK JEREMY PAUL ; CONNELL SHEA PETER ; COOPER COLIN STEPHEN ;
CURLEY HELEN MARIE

Agent(s): LEONARD THOMAS

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU
CY CZ DE DJ DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL
IN IR IS IT JO JP KE KG KH KM KN KP KR KW KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN
MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI
SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW